恒瑞医药(01276.HK)2月4日耗资931.7万元回购16.5万股A股

Group 1 - The core point of the article is that Heng Rui Medicine (01276.HK) announced a share buyback on February 4, 2026, spending RMB 9.317 million to repurchase 165,000 A-shares at a price range of RMB 56.25 to 57.09 per share [1][1][1] Group 2 - Heng Rui Medicine's share buyback reflects the company's strategy to enhance shareholder value and confidence in its stock performance [1] - The company has also received acceptance for the marketing authorization application of "Injectable Phosphorlorapitant Palonosetron" from Fujian Shengdi Medicine [1]